Home › Mercks New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL (posaconazole) Receives FDA Priority Review
 

Keywords :   


Mercks New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL (posaconazole) Receives FDA Priority Review

2013-11-18 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Marketing Authorization Application also Filed with the European Medicines Agency WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous (IV) solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Language: English Contact: MerckMedia Contacts:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application drug priority

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
More »